



## Immunoglobulin E (IgE) Test System Product Code: 2525-300

### 1.0 INTRODUCTION

**Intended Use: The Quantitative Determination of Immunoglobulin E (IgE) Concentration in Human Serum by a Microplate Enzyme Immunoassay, Colorimetric**

### 2.0 SUMMARY AND EXPLANATION OF THE TEST

Allergic reactions, which are becoming more widespread, are usually diagnosed on the basis of medical history and clinical symptoms. In vitro and in vivo testing, however, play a key role in confirming clinical suspicions and tailoring treatment. The measurement of immunoglobulin E (IgE) in serum is widely used in the diagnosis of allergic reactions and parasitic infections. Many allergies are caused by the immunoglobulins of subclass IgE acting as point of contact between the allergen and specialized cells. The IgE molecules (MW 200,000) bind to the surface of the mast cells and basophilic granulocytes. Subsequently the binding of allergen to cell-bound IgE causes these cells to release histamines and other vasoactive substances. The release of histamines in the body results initiates what is commonly known as an allergic reaction.

Before making any therapeutic determination it is important, however, to know whether the allergic reaction is IgE mediated or non-IgE mediated. Measurement of total IgE in serum sample, along with other supporting diagnostic information, can help to make that determination. Measurement of total circulating IgE may also be of value in the early detection of allergy in infants and as a means of predicting future atopic manifestations. Before deciding on any therapy it is important to take into consideration all the relevant clinical information as well as information supplied by specific allergy testing.

IgE levels show a slow increase during childhood, reaching adult levels in the second decade of life. In general, the total IgE levels increase with the allergies a person has and the number of times of exposure to the relevant allergens. Significant elevations may be seen in the sensitized individuals, but also in cases of myeloma, pulmonary aspergillosis, and during the active stages of parasitic infections.


In this method, IgE calibrator, patient specimen or control is first added to a streptavidin coated well. Biotinylated monoclonal antibody (specific for IgE) is added and the reactants mixed. Reaction between the IgE antibodies and native IgE forms complex that binds with the streptavidin coated to the well. The excess serum proteins are washed away via a wash step. Another enzyme labeled monoclonal antibody specific to IgE is added to the wells. The enzyme labeled antibody binds to the IgE already immobilized on the well through its binding with the biotinylated monoclonal antibody. Excess enzyme is washed off via a wash step. A color is generated by the addition of a substrate. The intensity of the color generation is directly proportional to the concentration of the IgE in the sample.

### 3.0 PRINCIPLE

#### Immunoenzymometric sequential assay (TYPE 4):


The essential reagents required for an immunoenzymometric assay include high affinity and specificity antibodies (enzyme and immobilized), with different and distinct epitope recognition, in excess, and native antigen. In this procedure, the immobilization takes place during the assay at the surface of a microplate well through the interaction of streptavidin coated on the well and exogenously added biotinylated monoclonal anti-IgE antibody.

Upon mixing monoclonal biotinylated antibody, and a serum containing the native antigen, reaction results between the native antigen and the antibody, forming an antibody-antigen complex. The interaction is illustrated by the following equation:




$\text{B}^{\text{in}}\text{Ab}_{(\text{m})}$  = Biotinylated Monoclonal Antibody (Excess Quantity)  
 $\text{Ag}_{(\text{IgE})}$  = Native Antigen (Variable Quantity)  
 $\text{Ag}_{(\text{IgE})} - \text{B}^{\text{in}}\text{Ab}_{(\text{m})}$  = Antigen-Antibody complex (Variable Quantity)  
 $k_a$  = Rate Constant of Association  
 $k_{-a}$  = Rate Constant of Disassociation

Simultaneously, the complex is deposited to the well through the high affinity reaction of streptavidin and biotinylated antibody. This interaction is illustrated below:



After a suitable incubation period, the antibody-antigen bound fraction is separated from unbound antigen by decantation or aspiration. Another antibody (directed at a different epitope) labeled with an enzyme is added. Another interaction occurs to form an enzyme labeled antibody-antigen-biotinylated-antibody complex on the surface of the wells. Excess enzyme is washed off via a wash step. A suitable substrate is added to produce color measurable with the use of a microplate spectrophotometer. The enzyme activity on the well is directly proportional to the native antigen concentration. By utilizing several different serum references of known antigen concentration, a dose response curve can be generated from which the antigen concentration of an unknown can be ascertained.



$\text{EnzAb}_{(\text{x-IgE})}$  = Enzyme labeled Antibody (Excess Quantity)  
 $\text{EnzAb}_{(\text{x-IgE})} - \text{IC}$  = Antigen-Antibodies Complex  
 $k_b$  = Rate Constant of Association  
 $k_{-b}$  = Rate Constant of Disassociation

### 4.0 REAGENTS

#### Materials Provided:

##### A. IgE Calibrators – 1.0 ml/vial - Icons A-F

Six (6) vials of human serum based reference calibrators at concentrations of 0 (A), 5 (B), 25 (C), 50 (D), 150 (E) and 400 (F) IU/ml. Store at 2-8°C. A preservative has been added.

**Note:** The Calibrators are standardized against WHO's 2ndIRP 75/502 for IgE

##### B. IgE Biotin Reagent – 13 ml/vial - Icon ▽

One (1) vial containing biotinylated anti-human IgE mIgG reagent presented in a protein-stabilized matrix. A preservative has been added. Store at 2-8°C.

##### C. IgE Enzyme Reagent – 13 ml/vial - Icon ☒

One (1) vial containing anti-human IgE-HRP incorporated complex in a protein-stabilized matrix. A preservative has been added. Store at 2-8°C.

##### D. Streptavidin Plate – 96 wells - Icon ▽

One 96-well microplate coated with streptavidin and packaged in an aluminum bag with a drying agent. Store at 2-8°C.

##### E. Wash Solution Concentrate – 20ml/vial - Icon ♣

One (1) vial containing a surfactant in buffered saline. A preservative has been added. Store at 2-8°C.

##### F. Substrate A – 7.0ml/vial - Icon S<sup>A</sup>

One (1) vial containing tetramethylbenzidine (TMB) in acetate buffer. Store at 2-8°C.

##### G. Substrate B – 7.0ml/vial - Icon S<sup>B</sup>

One (1) vial containing hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) in acetate buffer. Store at 2-8°C.

##### H. Stop Solution – 8.0ml/vial - Icon ☒

One (1) vial containing a strong acid (1N HCl). Store at 2-8°C.

#### I. Product Instructions.

**Note 1:** Do not use reagents beyond the kit expiration date.

**Note 2:** Avoid extended exposure to heat and light. **Opened reagents are stable for sixty (60) days when stored at 2-8°C. Kit and component stability are identified on label.**

**Note 3:** Above reagents are for a single 96-well microplate.

#### 4.1 Required But Not Provided:

- Pipette capable of delivering 0.025 and 0.050ml (25 & 50µl) volumes with a precision of better than 1.5%.
- Dispenser(s) for repetitive deliveries of 0.100 and 0.350ml (100 & 350µl) volumes with a precision of better than 1.5%.
- Microplate washers or a squeeze bottle (optional).
- Microplate Reader with 450nm and 620nm wavelength absorbance capability.
- Absorbent Paper for blotting the microplate wells.
- Plastic wrap or microplate cover for incubation steps.
- Vacuum aspirator (optional) for wash steps.
- Timer.
- Quality control materials.

### 5.0 PRECAUTIONS

**For In Vitro Diagnostic Use  
Not for Internal or External Use in Humans or Animals**

All products that contain human serum have been found to be non-reactive for Hepatitis B Surface Antigen, HIV 1&2 and HCV Antibodies by FDA licensed reagents. Since no known test can offer complete assurance that infectious agents are absent, all human serum products should be handled as potentially hazardous and capable of transmitting disease. Good laboratory procedures for handling blood products can be found in the Center for Disease Control / National Institute of Health, "Biosafety in Microbiological and Biomedical Laboratories," 2nd Edition, 1988, HHS Publication No. (CDC) 88-8395.

**Safe disposal of kit components must be according to local regulatory and statutory requirement.**

### 6.0 SPECIMEN COLLECTION AND PREPARATION

The specimens shall be blood serum in type and the usual precautions in the collection of venipuncture samples should be observed. For accurate comparison to established normal values, a fasting morning serum sample should be obtained. The blood should be collected in a plain redtop venipuncture tube without additives or anti-coagulants. Allow the blood to clot for samples. Centrifuge the specimen to separate the serum from the cells.

**In patients receiving therapy with high biotin doses (i.e. >5mg/day), no sample should be taken until at least 8 hours after the last biotin administration, preferably overnight to ensure fasting sample.**

Samples may be refrigerated at 2-8°C for a maximum period of five (5) days. If the specimen(s) cannot be assayed within this time, the sample(s) may be stored at temperatures of -20°C for up to 30 days. Avoid use of contaminated devices. Avoid repetitive freezing and thawing. When assayed in duplicate, 0.050ml (50µl) of the specimen is required.

### 7.0 QUALITY CONTROL

Each laboratory should assay controls at levels in the low, normal and elevated range for monitoring assay performance. These controls should be treated as unknowns and values determined in every test procedure performed. Quality control charts should be maintained to follow the performance of the supplied reagents. Pertinent statistical methods should be employed to ascertain trends. Significant deviation from established performance can indicate unnoticed change in experimental conditions or degradation of kit reagents. Fresh reagents should be used to determine the reason for the variations

### 8.0 REAGENT PREPARATION

- Wash Buffer**  
Dilute contents of wash concentrate to 1000ml with distilled or deionized water in a suitable storage container. Storediluted buffer at 2-30°C for up to 60 days.
- Working Substrate Solution** – Stable for one year  
Pour the contents of vial labeled Solution 'A' into the vial labeled Solution 'B'. Place the yellow cap on the mixed reagent for easy identification. Mix and label accordingly. Store at 2-8 °C.

**Note 1: Do not use the working substrate if it looks blue.  
Note 2: Do not use reagents that are contaminated or have bacteria growth.**

### 9.0 TEST PROCEDURE

*Before proceeding with the assay, bring all reagents, serum reference calibrators and controls to room temperature (20-27°C).  
\*\*\*Test procedure should be performed by a skilled individual or trained professional\*\*\**

- Format the microplates' wells for each serum reference calibrator, control and patient specimen to be assayed in duplicate. **Replace any unused microwell strips back into the aluminum bag, seal and store at 2-8°C.**
- Pipette 0.025 ml (25µl) of the appropriate serum reference calibrator, control or specimen into the assigned well.
- Add 0.100 ml (100µl) of the IgE Biotin Reagent to each well. **It is very important to dispense all reagents close to the bottom of the coated well.**
- Swirl the microplate gently for 20-30 seconds to mix and cover.
- Incubate 30 minutes at room temperature.
- Discard the contents of the microplate by decantation or aspiration. If decanting, tap and blot the plate dry with absorbent paper.
- Add 0.350ml (350µl) of wash buffer (see Reagent Preparation Section), decant (tap and blot) or aspirate. Repeat two (2) additional times for a total of three (3) washes. **An automatic or manual plate washer can be used. Follow the manufacturer's instruction for proper usage. If a squeeze bottle is employed, fill each well by depressing the container (avoiding air bubbles) to dispense the wash. Decant the wash and repeat two (2) additional times.**
- Add 0.100 ml (100µl) of the IgE Enzyme Reagent labeled antibody to each well.  
**DO NOT SHAKE THE PLATE AFTER ENZYME ADDITION**
- Cover and incubate 30 minutes at room temperature.
- Discard the contents of the microplate by decantation or aspiration. If decanting, blot the plate dry with absorbent paper.
- Add 0.350ml (350µl) of wash buffer (see Reagent Preparation Section), decant (tap and blot) or aspirate. Repeat two (2) additional times for a total of three (3) washes. **An automatic or manual plate washer can be used. Follow the manufacturer's instruction for proper usage. If a squeeze bottle is employed, fill each well by depressing the container (avoiding air bubbles) to dispense the wash. Decant the wash and repeat two (2) additional times.**
- Add 0.100 ml (100µl) of working substrate solution to all wells (see Reagent Preparation Section). **Always add reagents in the same order to minimize reaction time.  
DO NOT SHAKE THE PLATE AFTER SUBSTRATE ADDITION**
- Incubate at room temperature for fifteen (15) minutes.
- Add 0.050ml (50µl) of stop solution to each well and gently mix for 15-20 seconds.
- Read the absorbance in each well at 450nm (using a reference wavelength of 620-630nm to minimize well imperfections) in a microplate reader. **The results should be read within thirty (30) minutes of adding the stop solution.**

### 10.0 CALCULATION OF RESULTS

A dose response curve is used to ascertain the concentration of IgE in unknown specimens.

- Record the absorbance obtained from the printout of the microplate reader as outlined in Example 1.
- Plot the absorbance for each duplicate serum reference versus the corresponding IgE concentration in IU/ml on linear graph

paper (do not average the duplicates of the serum references before plotting).


- Draw the best-fit curve through the plotted points.
- To determine the concentration of IgE for an unknown, locate the average absorbance of the duplicates for each unknown on the vertical axis of the graph, find the intersecting point on the curve, and read the concentration (in IU/ml) from the horizontal axis of the graph (the duplicates of the unknown may be averaged as indicated). In the following example, the average absorbance (1.323) intersects the dose response curve at 142 IU/ml IgE concentration (See Figure 1).

**Note:** Computer data reduction software designed for ELISA assays may also be used for the data reduction. If such software is utilized, the validation of the software should be ascertained.

#### EXAMPLE 1

| Sample I.D. | Well | Abs   | Mean Abs (B) | Conc  |
|-------------|------|-------|--------------|-------|
| Cal A       | A1   | 0.014 | 0.015        | 0     |
|             | B1   | 0.016 |              |       |
|             | C1   | 0.072 |              |       |
| Cal B       | D1   | 0.074 | 0.073        | 5     |
|             | E1   | 0.364 |              |       |
|             | F1   | 0.326 |              |       |
| Cal C       | G1   | 0.663 | 0.639        | 50    |
|             | H1   | 0.614 |              |       |
|             | A2   | 1.340 |              |       |
| Cal D       | B2   | 1.388 | 1.364        | 150   |
|             | C2   | 2.601 |              |       |
|             | D2   | 2.682 |              |       |
| Cal E       | E2   | 2.575 | 2.562        | 375.3 |
|             | F2   | 2.549 |              |       |
|             | G2   | 0.818 |              |       |
| Cal F       | H2   | 0.807 | 0.813        | 71.2  |
|             | A3   | 1.322 |              |       |
|             | B3   | 1.324 |              |       |
| Ctrl 1      |      |       | 2.641        | 400   |
|             |      |       |              |       |
|             |      |       |              |       |
| Ctrl 2      |      |       | 2.641        | 400   |
|             |      |       |              |       |
|             |      |       |              |       |
| Patient 1   |      |       | 1.323        | 142.0 |
|             |      |       |              |       |
|             |      |       |              |       |

Figure 1



\*The data presented in Example 1 and Figure 1 is for illustration only and **should not** be used in lieu of a standard curve prepared with each assay.

#### 11.0 Q.C. PARAMETERS

In order for the assay results to be considered valid the following criteria should be met:

- The absorbance (OD) of calibrator 'A' should be  $\leq 0.05$
- The absorbance (OD) of calibrator 'F' should be  $\geq 1.3$
- Four out of six quality control pools should be within the established ranges.

#### 12.0 RISK ANALYSIS

The MSDS and Risk Analysis Form for this product are available on request from Monobind Inc.

##### 12.1 Assay Performance

- It is important that the time of reaction in each well is held constant to achieve reproducible results.
- Pipetting of samples should not extend beyond ten (10) minutes to avoid assay drift.
- Highly lipemic, hemolyzed or grossly contaminated specimen(s) should not be used.
- If more than one (1) plate is used, it is recommended to repeat the dose response curve.
- The addition of substrate solution initiates a kinetic reaction, terminated by the addition of the stop solution. Therefore, the

substrate and stop solution should be added in the same sequence to eliminate any time-deviation during reaction.

- Plate readers measure vertically. Do not touch the bottom of the wells.
- Failure to remove adhering solution adequately in the aspiration or decantation wash step(s) may result in poor replication and spurious results.
- Use components from the same lot. No intermixing of reagents from different batches.
- Accurate and precise pipetting, as well as following the exact time and temperature requirements prescribed are essential. Any deviation from Monobind IFU may yield inaccurate results.
- All applicable national standards, regulations and laws, including, but not limited to, good laboratory procedures, must be strictly followed to ensure compliance and proper device usage.
- It is important to calibrate all the equipment e.g. Pipettes, Readers, Washers and/or the automated instruments used with this device, and to perform routine preventative maintenance.
- Risk Analysis- as required by CE Mark IVD Directive 98/79/EC - for this and other devices, made by Monobind, can be requested via email from [Monobind@monobind.com](mailto:Monobind@monobind.com).

#### 12.2 Interpretation

- Measurements and interpretation of results must be performed by a skilled individual or trained professional.**
- Laboratory results alone are only one aspect for determining patient care and should not be the sole basis for therapy, particularly if the results conflict with other determinants.
- The reagents for the test system have been formulated to eliminate maximal interference; however, potential interaction between rare serum specimens and test reagents can cause erroneous results. Heterophilic antibodies often cause these interactions and have been known to be problems for all kinds of immunoassays (Boscato LM, Stuart MC. "Heterophilic antibodies: a problem for all immunoassays" Clin. Chem. 1988;34:27-33). For diagnostic purposes, the results from this assay should be in combination with clinical examination, patient history and all other clinical findings.
- For valid test results, adequate controls and other parameters must be within the listed ranges and assay requirements.
- If test kits are altered, such as by mixing parts of different kits, which could produce false test results, or if results are incorrectly interpreted, **Monobind shall have no liability.**
- If computer controlled data reduction is used to interpret the results of the test, it is imperative that the predicted values for the calibrators fall within 10% of the assigned concentrations.
- Serum IgE concentration is dependent upon a multiplicity of factors: including if the patient is sensitized, how many times the patient has been exposed to a specific allergen etc. Total IgE concentration alone is not sufficient to assess the clinical status. All the clinical findings especially specific allergy testing should be taken into consideration while determining the clinical status of the patient.
- Since all atopic reactions are not IgE mediated, all relevant clinical information should be taken into consideration before making any determination for patients who may be in the normal range.

#### 13.0 EXPECTED RANGES OF VALUES

A study of population from different age groups was conducted to evaluate the IgE AccuBind® ELISA test system. The results are presented in Table 1:

| TABLE 1<br>Expected Values for the IgE (In IU/ml) |            |        |                |
|---|------------|--------|----------------|
| Age (Yrs)   | Number (n) | Median | Absolute Range |
| 0-3   | 31         | 6.4    | ND - 46        |
| 3-16  | 43         | 25.0   | ND - 280       |
| Adult   | 145        | 43     | 0 - 200        |

It is important to keep in mind that establishment of a range of values which can be expected to be found by a given method for a population of "normal"-persons is dependent upon a multiplicity of factors: the specificity of the method, the population tested and the precision of the method in the hands of the analyst. For these reasons each laboratory should depend upon the range of expected values established by the Manufacturer only until an in-house range can be determined by the analysts using the method with a population indigenous to the area in which the

laboratory is located.

#### 14.0 PERFORMANCE CHARACTERISTICS

##### 14.1 Precision

The within and between assay precision of the IgE AccuBind® ELISA Test System were determined by analyses on three different levels of pool control sera. The number, mean value, standard deviation and coefficient of variation for each of these control sera are presented in Table 2 and Table 3.

| TABLE 2<br>Intra-Assay Precision (in IU/ml) |    |       |          |       |
|---|----|-------|----------|-------|
| SAMPLE                                      | N  | X     | $\sigma$ | C.V.% |
| Low   | 20 | 48.9  | 2.87     | 5.87  |
| Medium                                      | 20 | 160.5 | 6.47     | 4.03  |
| High  | 20 | 297.6 | 5.81     | 1.95  |

| TABLE 3<br>Inter Assay Precision (in IU/ml) |    |       |          |       |
|---|----|-------|----------|-------|
| SAMPLE                                      | N  | X     | $\sigma$ | C.V.% |
| Low   | 10 | 46.3  | 3.9      | 8.42  |
| Medium                                      | 10 | 157.0 | 7.3      | 4.64  |
| High  | 10 | 301.0 | 10.6     | 3.52  |

##### 14.2 Sensitivity

The IgE AccuBind® ELISA test system has a sensitivity of 0.125 IU/ml. The sensitivity was ascertained by determining the variability of the 0 IU/ml serum calibrator and using the  $2\sigma$  (95% certainty) statistics to calculate the minimum dose.

##### 14.3 Accuracy

The IgE AccuBind® ELISA test system was compared with a reference method. Biological specimens with IgE levels in the low, medium and high ranges were used. The values ranged from 0.8 to 3100 IU/ml. The total number of such specimens was 219. The least square regression equation and the correlation coefficient were computed for this IgE AccuBind® ELISA method in comparison with the predicate method (Table 4):

| TABLE 4       |      |                                  |                         |
|---------------|------|----------------------------------|-------------------------|
| Method        | Mean | Least Square Regression Analysis | Correlation Coefficient |
| Monobind (X)  | 179  | $x = -12.9 + 1.21(Y)$            | 0.967                   |
| Predicate (Y) | 157  |                                  |                         |

Only slight amounts of bias between this method and the reference method are indicated by the closeness of the mean values. The least square regression equation and correlation coefficient indicates excellent method agreement.

##### 14.4 Specificity

The specificity of the IgE AccuBind® ELISA test system, to closely related immunoglobulins was evaluated by adding those at twice the physiological concentrations to a serum matrix. No cross-reaction between the antibodies used and the related molecules was detected.

##### 14.5 High Dose Effect

Since the assay is sequential in design, high concentrations of IgE do not show the hook effect. Myeloma IgE patient samples with concentrations over 8 million IU/ml demonstrated extremely high levels of absorbance.

##### 14.6 Linearity

Two patient pools were assayed diluted (in 'A' Calibrator) and undiluted with the IgE AccuBind® ELISA test system. The observed and expected values are listed below in Table 5:

| TABLE 5   |                      |                      |                  |
|-----------|----------------------|----------------------|------------------|
| Sample    | Observed (O) (IU/ml) | Expected (E) (IU/ml) | % Recovery (O/E) |
| Pool 1    | 106.8                | -                    | -                |
| Pool 1/2  | 50.8                 | 53.4                 | 95.1             |
| Pool 1/4  | 25.3                 | 26.7                 | 94.8             |
| Pool 1/8  | 13.4                 | 13.3                 | 100.6            |
| Pool 1/16 | 6.6                  | 6.7                  | 98.5             |
| Pool 2    | 395.9                | -                    | -                |
| Pool 2/2  | 189.5                | 197.9                | 95.8             |
| Pool 2/4  | 106.1                | 98.9                 | 107.2            |
| Pool 2/8  | 48.0                 | 49.5                 | 96.9             |
| Pool 2/16 | 25.8                 | 24.7                 | 104.2            |

#### 14.7 Recovery

Two patient pools were spiked with known amounts of IgE and assayed with the IgE AccuBind® ELISA test system. The observed and expected values are listed below in Table 6.

| TABLE 6     |                      |                      |                  |
|-------------|----------------------|----------------------|------------------|
| Sample      | Observed (O) (IU/ml) | Expected (E) (IU/ml) | % Recovery (O/E) |
| Pool 1      | 25.7                 | -                    | -                |
| Pool 1+ 25  | 50.7                 | 50.7                 | 100.0            |
| Pool 1+ 50  | 74.8                 | 75.7                 | 101.2            |
| Pool 1+ 100 | 122.7                | 125.7                | 97.6             |
| Pool 1+ 200 | 232.0                | 225.7                | 102.7            |
| Pool 2      | 12.3                 | -                    | -                |
| Pool 2+ 25  | 41.7                 | 37.3                 | 111.2            |
| Pool 2+ 50  | 62.6                 | 62.3                 | 100.6            |
| Pool 2+ 100 | 109.4                | 112.3                | 97.4             |
| Pool 2+ 200 | 197.2                | 212.3                | 92.8             |

#### 15.0 REFERENCES

- Plebani M, Bernardi D, Basso D, Faggiani, D and Borghesan F, "Measurement of specific immunoglobulin E: intermethod comparison and standardization", *Clin Chem*, 44, 9 (1998).
- Geha RS, "Human IgE", *J Clinical Immunology*, 74, 109-120 (1984).
- Barbee RA, et al, "Distribution of IgE in a community population sample: correlation with age, sex and allergen skin reactivity", *J of Clinical Immunology*, 68, 106-111 (1981).
- Nye L, Marrett TG., Landon J, White RJ, "A detailed investigation of circulating levels of IgE in a normal population", *Clin Allergy*, 1, 13-24 (1975).
- Mandy FF, Perelmutter L, "Laboratory measurement of total human serum IgE", *Journal Clinical Immunoassay*, 6(2), 140-146 (1983).
- Hamilton RG, Adkinson RF, "Clinical laboratory methods and allergic disease", *Lab Management*, 21(12), 37-50 (1983).
- Halpern GM, "Markers of human allergic disease", *J Clin Immunoassay*, 6(2), 131-139 (1983).
- Hornberger HA, Yuninger JW, "Laboratory testing in the diagnosis and management of allergic diseases", *Clin Lab*, 2, 351-388 (1983).
- National Committee for Clinical Laboratory Standards: Procedures for the collection of blood specimens by venipuncture 3<sup>rd</sup> Ed, NCCLS Doc H3-A3 (1991).
- Tietz NW, *Clinical Guide to Laboratory Tests*, 3<sup>rd</sup> Ed, Philadelphia, WB Saunders 358 (1995).

Revision: 4 Date: 2019-Jul-16 DCO: 1353  
MP2525 Product Code: 2525-300

For Orders and Inquires, please contact

**Monobind Inc.**  
100 North Pointe Drive  
Lake Forest, CA 92630 USA

Tel: +1 949.951.2665 Mail: [info@monobind.com](mailto:info@monobind.com)  
Fax: +1 949.951.3539 Fax: [www.monobind.com](http://www.monobind.com)



Please visit our website to learn more about our products and services.

##### Glossary of Symbols (EN 960/ISO 15223)

